N-[2-(1H-indol-3-yl)ethyl]-2-nitroaniline | 903361-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-[2-(1H-indol-3-yl)ethyl]-2-nitroaniline
• 英文别名: N-(2-nitrophenyl)tryptamine
• CAS: 903361-73-9
• 化学式: C₁₆H₁₅N₃O₂
• 分子量: 281.314
• InChiKey: CMXMTUKCCBLGIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  73.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  色胺 、 1-氟-2-硝基苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.17h， 以60%的产率得到N-[2-(1H-indol-3-yl)ethyl]-2-nitroaniline
  参考文献：
  名称：

  Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents

  摘要：

  本发明涉及取代芳基化合物，其通过各种连接剂与取代吲哚基团相连，并且这些药剂的酮尿氨酸/酮尿胺类似物以及它们的制备和含有这些化合物的药物组合物。本发明进一步涉及这些化合物用于抑制GSK3β激酶和/或调节N-甲基-D-天冬氨酸(NMDA)通道活性，用于治疗神经退行性和其他疾病的药物用途。

  公开号：

  US20080132559A1

文献信息

• Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
  申请人：NEURIM PHARMACEUTICALS (1991) LIMITED

  公开号：EP2664615A1

  公开（公告）日：2013-11-20

  This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and/or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.

  本发明涉及通过各种连接剂与取代的吲哚分子相连的取代芳基化合物，以及这些制剂的犬尿氨酸/犬尿氨酸样代谢物、其制备方法和含有这些化合物的药物组合物。本发明进一步涉及这些化合物的药物用途，用于抑制 GSK3β 激酶和/或调节 N-甲基-D-天冬氨酸（NMDA）通道活性，以治疗神经退行性疾病和其他疾病。
• Mesoscale Flow Chemistry:  A Plug-Flow Approach to Reaction Optimisation
  作者：Rob C. Wheeler、Otman Benali、Martyn Deal、Elizabeth Farrant、Simon J. F. MacDonald、Brian H. Warrington

  DOI：10.1021/op7000707

  日期：2007.7.1

  In recent years, chemistry in flowing systems has become more prominent as a method of carrying out chemical transformations, ranging in scale from analytical-scale (microchemistry) through to kilogram-scale synthesis (macrochemistry). The advantages are readily apparent-increased control of conditions leading to greater reproducibility, scaleability, and increased safety/reduced loss-although its acceptance as a viable synthesis technique has been limited due to its drawbacks, primarily precipitation, liquid handling, and diffusion of the reaction within the reactor. Here, we present details of a system which bridges the gap between micro- and macroreactors and has enabled fast reaction optimisation (using small amounts of reagents) and subsequent multigram scale-up using a commercial reactor.
• SUBSTITUTED ARYL-INDOLE COMPOUNDS AND THEIR KYNURENINE/KYNURAMINE-LIKE METABOLITES AS THERAPEUTIC AGENTS
  申请人：NEURIM PHARMACEUTICALS (1991) LIMITED

  公开号：EP2086932B1

  公开（公告）日：2014-08-27
• FLOW REACTOR METHOD AND APPARATUS
  申请人：Benali Otman

  公开号：US20090142845A1

  公开（公告）日：2009-06-04

  A method of conducting a chemical reaction in a flow reactor comprises the steps of pumping at least one liquid reaction plug bounded at both ends by liquid spacer plugs along a reaction channel of the reactor; and conducting the chemical reaction in the reaction plug inside the reaction channel, wherein the liquid reaction plug comprises one or more reagents dispersed in a reaction solvent, the liquid spacer plugs are immiscible in the reaction solvent, and the reagents are substantially insoluble in the spacer plugs; and wherein the aspect ratio of the at least one reaction plug is at least about 10.
• US7622495B2
  申请人：——

  公开号：US7622495B2

  公开（公告）日：2009-11-24